COLUCID PHARMACEUTICALS, INC. (CLCD) financial statements (2020 and earlier)

Company profile

Business Address 222 THIRD STREET
CAMBRIDGE, MA 02142
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2016
TTM
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 65
Cash and cash equivalents 28
Short-term investments 37
Prepaid expense 1
Total current assets: 65
Noncurrent Assets
Other noncurrent assets 0
Total noncurrent assets: 0
TOTAL ASSETS: 65
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 5
Accounts payable 2
Accrued liabilities 4
Total current liabilities: 5
Noncurrent Liabilities
Liabilities, other than long-term debt 2
Deferred revenue and credits 2
Total noncurrent liabilities: 2
Total liabilities: 7
Stockholders' equity
Stockholders' equity attributable to parent 58
Common stock 0
Additional paid in capital 146
Accumulated other comprehensive loss (0)
Accumulated deficit (87)
Total stockholders' equity: 58
TOTAL LIABILITIES AND EQUITY: 65

Income statement (P&L) ($ in millions)

9/30/2016
TTM
12/31/2015
Operating expenses (31)
Operating loss: (31)
Nonoperating income
(Investment Income, Nonoperating)
 0
Net loss attributable to parent: (31)
Preferred stock dividends and other adjustments (13)
Net loss available to common stockholders, basic: (43)
Other undisclosed net income available to common stockholders, diluted 5
Net loss available to common stockholders, diluted: (38)

Comprehensive Income ($ in millions)

9/30/2016
TTM
12/31/2015
Net loss: (31)
Other comprehensive loss (0)
Comprehensive loss, net of tax, attributable to parent: (31)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: